Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants (Fase1B)

This study has been completed.
Sponsor:
Collaborators:
Centro médico Imbanaco
Asoclinic Laboratorio de Inmunología
Information provided by:
Malaria Vaccine and Drug Development Center
ClinicalTrials.gov Identifier:
NCT01081847
First received: March 3, 2010
Last updated: March 5, 2010
Last verified: March 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2006
  Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)